Financial Performance
Asarfi Hospital’s financial trajectory in FY26 was characterized by strong top-line and bottom-line expansion. The company reported a consolidated revenue of ₹173.5 crore, a significant jump from the previous fiscal. This growth was mirrored in the Profit After Tax, which surged 58% to reach ₹16.7 crore.
While the EBITDA margin remained steady at 20%, the management indicated that improving the case mix and increasing surgical volumes are expected to drive margins toward the 23-25% range by FY28. The current Price-to-Earnings (PE) ratio of 22.52 stands notably lower than the industry average of 63.88.
Management Outlook
Management expressed high confidence in achieving a revenue target of ₹260 crore for FY27, representing a projected growth of approximately 50%. Looking further ahead, the company aims to touch the ₹400 crore revenue milestone by FY28 by scaling bed capacity to over 500 units. A long-term vision to reach 1,000 beds by FY30 was also shared.
Additionally, the company plans to migrate from the SME platform to the main board after becoming eligible in July, a move intended to enhance liquidity and institutional participation in the stock.
Business Overview
Based in Jharkhand, Asarfi Hospital is a multi-specialty healthcare provider with a growing focus on tertiary care. The company’s specialized units, particularly the Cancer Hospital, saw revenue grow from ₹20 crore to ₹33 crore with a current utilization rate of 42%. The facility has integrated high-end diagnostic equipment, including the GE dual-detector SPECT gamma camera and a Philips Azurion cath lab, to bolster its oncology and cardiology segments.
The hospital currently serves a vast catchment area covering 10 neighboring districts, with a pricing strategy that leverages its regional dominance.
Sector Dynamics
The healthcare sector in India is witnessing increased demand for high-quality tertiary care in tier-2 and tier-3 cities. Asarfi Hospital is capitalizing on this trend by expanding its reach beyond Dhanbad. However, the management highlighted regulatory hurdles, such as procedural delays in Jharkhand’s organ transplant policy, which have impacted the operationalization of bone marrow facilities.
Dependency on government schemes like Ayushman Bharat remains high, which influences cash realization cycles and receivable aging, a common factor across regional healthcare providers servicing low-to-middle-income populations.
What to Watch
- Progress on the implementation of the organ transplant policy in Jharkhand to operationalize bone marrow facilities.
- Execution of the planned ₹15 crore capital expenditure for research institutes and facility upgrades.
- Eligibility and timeline for the migration from the SME platform to the Main Board after July.
- Sustainability of the 22-25% EBITDA margin guidance as the company scales to 500+ beds.
- Improvement in the aging of receivables related to the Ayushman Bharat government scheme.
